Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

PhRMA Drug Pricing Comments Mainly Stick To Script

With only one new proposal, brand industry association seems to banking on strength of past policy positions as Trump's drug pricing blueprint moves towards implementation stage.

Pricing Debate Regulation Reimbursement

Latest From Pricing Debate

To Lower Drug Prices, Look At Generic Industry Health Rather Than FDA, Woodcock Says

US FDA can encourage and increase competition, but cannot force generic companies to enter markets deemed unprofitable, CDER director says.
Pricing Debate Generic Drugs

PBM Trade Group Taps Medical Device Lobbyist Scott As CEO

AdvaMed Chief Advocacy Officer JC Scott will take the reins at PCMA in mid-October.

Pharmacy Benefit Management Leadership

PCMA’s Merritt Reflects On 15 Years At The Helm Of PBM Advocacy

Outgoing Pharmaceutical Care Management Association chief discusses fight over rebates, future of pharmacy benefit management, opportunities and challenges facing his successor.

Pharmacy Benefit Management Policy

Dutch Insurer Seeks €4m from AZ Over ‘High’ Seroquel Price

AstraZeneca is being pursued in court for compensation over what a health insurer calls the “unnecessarily high price” that the company charged for Seroquel.

Pricing Debate Reimbursement

Medicare Part D ‘Modernization’ Policies Still Priority Reforms – OMB’s Grogan

Office of Management and Budget health programs official highlights the Administration’s plan for updating and lowering costs in Medicare Part D, including point-of-sale rebates.

Pricing Debate Regulation

DTC Ad Price Disclosure Provision Stripped From US Funding Bill

Even though measure was blocked in Congress, it may still advance through regulation.

Pricing Debate Advertising, Marketing & Sales

HHS Secretary Alex Azar Talks Rebate Changes, But Not Eliminating Discounts Altogether

Details on anticipated changes to rebate practices are in demand. HHS Secretary Azar talked about changes that would still allow negotiated discounts at the point of sale during a presentation at the FT Pharma Pricing and Value Summit.

Market Access Pricing Debate

HHS Secretary Alex Azar Talks Rebate Changes, But Not Eliminating Discounts Altogether

Details on anticipated changes to rebate practices are in demand. HHS Secretary Azar talked about changes that would still allow negotiated discounts at the point of sale during a presentation at the FT Pharma Pricing and Value Summit.

Market Access Pricing Debate

J&J Well Positioned For US Drug Pricing Changes Regardless Of Timing Or Form, Duato Says

Boasting of 14 current or near-term blockbusters and success staving off Remicade biosimilars, Johnson & Johnson says its growth derives 100% from sales volume, not price increases. All the same, it continues call for slow pricing reform.

Commercial Pricing Debate
See All
UsernamePublicRestriction

Register